It is possible that variations in CNT1 functionality may be a contributing factor to the poor efficacy of nucleoside analogs, as some patients with CNT1 deficiencies (e.g., due to renal diseases, CNT polymorphisms) may simply eliminate more drug in the urine, making less drug available for action on tumor tissues. The gene discussed is SLC28A1; the disease is neoplasm.